This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Adaptive Biotechnologies (ADPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.33% and 3.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Work-From-Home Push Drive Microsoft (MSFT) Q4 Earnings?
by Zacks Equity Research
Microsoft's (MSFT) fiscal fourth-quarter results are likely to reflect momentum in Azure, impressive Teams user growth led by coronavirus-induced work-from-home wave and uptick in Surface devices.
How Adaptive Biotechnologies (ADPT) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Microsoft (MSFT) and Adaptive Roll Out ImmuneCODE Database
by Zacks Equity Research
Microsoft (MSFT) and Adaptive Biotechnologies rolled out ImmuneCODE database in an effort to accelerate research and drive development of novel vaccines, diagnostics and therapeutics.
Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus
by Ritujay Ghosh
Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.
Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
by Ritujay Ghosh
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX
by Kinjel Shah
Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.
Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in the Cards for Cisco (CSCO) in Q3 Earnings?
by Zacks Equity Research
Cisco's (CSCO) fiscal third-quarter results are likely to reflect gains from strength in network security solutions and robust adoption of Webex triggered by coronavirus-led work-from-home wave.
Is a Beat in Store for Sunoco (SUN) This Earnings Season?
by Zacks Equity Research
Stable earnings from expansive fuel distribution assets are likely to have boosted Sunoco's (SUN) Q1 earnings.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Will Azure & Teams Adoption Aid Microsoft (MSFT) Q3 Earnings?
by Zacks Equity Research
Microsoft's (MSFT) fiscal third-quarter results are likely to reflect momentum in Azure, impressive Teams user growth led by coronavirus-induced work-from-home wave and uptick in Surface devices.
Microsoft (MSFT) to Report Q3 Results: What's in the Offing?
by Zacks Equity Research
Microsoft's (MSFT) fiscal third-quarter results are likely to reflect gains from strength in Azure and robust adoption of Teams triggered by coronavirus-led work-from-home wave.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Microsoft (MSFT) Partners GE Healthcare to Fight Coronavirus
by Zacks Equity Research
Microsoft (MSFT) inks deal with GE Healthcare to roll out patient monitoring software with an aim to limit COVID-19 exposure for medical staff and conserve PPEs.